Loading…
AVITA Medical, Inc. is projected to rise to $4.14 by 2027, a +2% move from its current price of $4.06. RCEL is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $3.89 | $4.06 | $4.23 | -0.03% |
| Jul 14 | $3.82 | $4.06 | $4.31 | -0.06% |
| Jul 15 | $3.77 | $4.06 | $4.36 | -0.09% |
| Jul 16 | $3.73 | $4.06 | $4.41 | -0.12% |
| Jul 17 | $3.69 | $4.05 | $4.45 | -0.15% |
| Jul 18 | $3.66 | $4.05 | $4.49 | -0.18% |
| Jul 19 | $3.63 | $4.05 | $4.53 | -0.21% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.63 | $4.05 | $4.53 | -0.21% |
| Week 2 | $3.46 | $4.04 | $4.73 | -0.42% |
| Week 3 | $3.33 | $4.03 | $4.89 | -0.63% |
| Week 4 | $3.23 | $4.03 | $5.02 | -0.83% |
| Week 5 | $3.14 | $4.02 | $5.15 | -1.04% |
| Week 6 | $3.06 | $4.01 | $5.26 | -1.25% |
| Week 7 | $2.98 | $4.00 | $5.36 | -1.46% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. Its lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions.
AVITA Medical also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2.
In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. AVITA Medical is headquartered in Valencia, California.
The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020.
AVITA Medical, Inc. trades under the RCEL symbol in the Healthcare sector. The current price is $4.30 per share and the market position reflects a market capitalization of $132.34M, with a rank of 4048.
The forecast outlook suggests a path from neutral in the early years to bullish in later years, with the average price rising from $4.30 in 2026 to $20.80 in 2050.
Key forecast milestones show a gradual rise in averages: 2026 avg $4.30, 2027 avg $4.39, 2028 avg $4.76, 2029 avg $4.17, 2030 avg $4.91, 2031 avg $6.61, 2032 avg $6.92, 2033 avg $6.96, 2034 avg $6.59, 2035 avg $6.75, 2040 avg $10.22, and 2050 avg $20.80.
A major floor 23.5% below — a decisive break under it would weaken the trend.
The nearest floor, 3.7% below — buyers have tended to step in here.
The nearest ceiling, 27.8% above — a clean break opens room to run.
A major ceiling 39.6% above — clearing it would confirm fresh momentum.
Key RCEL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RCEL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.66 | Sell | $4.46 | Sell |
| MA 10 | $4.54 | Sell | $4.47 | Sell |
| MA 20 | $4.24 | Sell | $4.37 | Sell |
| MA 50 | $4.27 | Sell | $4.32 | Sell |
| MA 100 | $4.40 | Sell | $4.32 | Sell |
| MA 200 | $4.22 | Sell | $4.66 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.03 | Neutral |
| Stoch RSI (14) | 9.77 | Buy |
| CCI (20) | -34.96 | Neutral |
| Williams %R (14) | -88.98 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 3.57 | Buy |
| Bollinger %B (20,2) | 0.39 | Neutral |
| Stochastic %K (14) | 11.02 | Buy |
| TRIX (15) | 0.24 | Buy |
| Awesome (5,34) | 0.40 | Buy |
| Ultimate (7,14,28) | 48.84 | Neutral |
| Momentum (10) | 0.14 | Buy |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 4.47 | Sell |
| ADX (14) | 16.76 | Neutral |
| ATR (14) | 0.18 | Info |
The near-term technical picture is bullish at the moment. RSI14 is 40, signaling room to move higher without being overbought.
The stock’s moving averages show SMA50 at $4.27 and SMA200 at $4.22, providing nearby support and a mild upward bias. Support is identified at $3.91 and resistance at $5.19, with the 30-day trading range spanning from $3.26 to $5.67.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.28 | $4.06 | $5.28 | 0% | Neutral | |
| $3.14 | $4.14 | $5.88 | +2% | Neutral | |
| $3.25 | $4.49 | $6.72 | +11% | Neutral | |
| $2.74 | $3.94 | $6.14 | -3% | Neutral | |
| $3.11 | $4.63 | $7.46 | +14% | Neutral | |
| $4.06 | $6.23 | $10.34 | +53% | Bullish | |
| $4.14 | $6.55 | $11.15 | +61% | Bullish | |
| $4.04 | $6.57 | $11.45 | +62% | Bullish | |
| $3.72 | $6.22 | $11.07 | +53% | Bullish | |
| $3.72 | $6.38 | $11.60 | +57% | Bullish | |
| $4.97 | $9.65 | $19.02 | +138% | Bullish | |
| $8.84 | $19.65 | $43.55 | +384% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.28 | $4.06 | $5.04 | +0.00% |
| August 2026 | $3.48 | $4.16 | $5.16 | +2.49% |
| September 2026 | $3.26 | $3.95 | $4.98 | -5.06% |
| October 2026 | $3.22 | $3.93 | $5.02 | -0.51% |
| November 2026 | $3.31 | $4.08 | $5.27 | +3.68% |
| December 2026 | $3.25 | $4.04 | $5.28 | -0.94% |
Click any year to see its month-by-month RCEL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, RCEL could reach as high as $5.28, with a base case around $4.06 and support toward $3.28 — roughly 0% from $4.06. A consolidation phase looks the most probable path here.
Expect RCEL to range from $3.14 to $5.88 through 2027. The $4.14 average target implies a +2% move from current prices. That is up +2% on the projected 2026 average. Price action looks broadly range-bound.
The RCEL price prediction for 2028 points to an average of $4.49 (low $3.25, high $6.72) — a potential gain of +11% on today's $4.06. A consolidation phase looks the most probable path here.
In 2029, RCEL is projected to trade between $2.74 and $6.14, averaging $3.94 — a potential decline of -3% from today's $4.06. That is -12% versus the projected 2028 average. Price action looks broadly range-bound.
AVITA Medical, Inc.'s 2030 outlook centres on $4.63, within a $3.11 to $7.46 range. That is up +17% on the projected 2029 average. That marks a +14% change versus current levels. A consolidation phase looks the most probable path here.
By 2031, RCEL could reach as high as $10.34, with a base case around $6.23 and support toward $4.06 — roughly +53% from $4.06. Momentum favours further upside here.
Expect RCEL to range from $4.14 to $11.15 through 2032. The $6.55 average target implies a +61% move from current prices. That is up +5% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The RCEL price prediction for 2033 points to an average of $6.57 (low $4.04, high $11.45) — a potential gain of +62% on today's $4.06. Momentum favours further upside here.
In 2034, RCEL is projected to trade between $3.72 and $11.07, averaging $6.22 — a potential gain of +53% from today's $4.06. That is -5% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
AVITA Medical, Inc.'s 2035 outlook centres on $6.38, within a $3.72 to $11.60 range. That is up +3% on the projected 2034 average. That marks a +57% change versus current levels. Momentum favours further upside here.
By 2040, RCEL could reach as high as $19.02, with a base case around $9.65 and support toward $4.97 — roughly +138% from $4.06. Buyers look set to stay in control over this stretch.
Expect RCEL to range from $8.84 to $43.55 through 2050. The $19.65 average target implies a +384% move from current prices. That is up +104% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in RCEL today (≈ 246.305419 RCEL) could be worth
$4,840.93
+$3,840.93 (+384%) by 2050 · US Dollar
Based on the average projected RCEL price of $19.65 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RCELwould be worth at today's price.
$1,000 invested in RCEL on Jul 10, 2025 (≈ 168.350167 RCEL) would be worth
$683.5
-$316.5 (-31.6%) today · 0.68× · US Dollar
Based on a RCEL entry price of $5.94 vs. today's $4.06.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.06 | $802.37 | -19.8% |
| 1 month ago | $4.12 | $985.44 | -1.5% |
| 3 months ago | $5.01 | $810.38 | -19.0% |
| 6 months ago | $3.42 | $1,187.13 | +18.7% |
| 1 year ago | $5.94 | $683.5 | -31.6% |
| All time (5.0y) ago | $19.52 | $207.99 | -79.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RCEL forecast.
Our base-case forecast reaches $8.10 around 2040.
Implied market cap at $8.10: $249.29M
The multi-year forecast points to a shift from neutral in the early years to bullish in the longer term. In 2026 the avg is $4.30 with a 0 ROI, followed by 2027 avg $4.39 (ROI 2.1) and 2028 avg $4.76 (ROI 10.7), then 2029 avg $4.17 (ROI -3.1).
From 2030 onward, the averages rise more decisively: 2030 avg $4.91 (ROI 14.2), 2031 avg $6.61 (ROI 53.8), 2032 avg $6.92 (ROI 61), 2033 avg $6.96 (ROI 61.8), 2034 avg $6.59 (ROI 53.4), 2035 avg $6.75 (ROI 57).
The forecast continues to higher levels with 2040 avg $10.22 (ROI 137.7) and 2050 avg $20.80 (ROI 383.7), signaling substantial long-term upside but with inherent uncertainty. These figures are not guarantees, and actual results may differ.
Tap a question to reveal the answer.
2030 min $3.30, avg $4.91, max $7.91; ROI 14.2; sentiment NEUTRAL.
The forecast shows neutral sentiment through 2029, then bullish from 2031 onward with higher averages and ROIs, culminating in an avg of $20.80 in 2050 and ROI of 383.7. However, outcomes are not guaranteed and depend on future conditions.
Yes. The 2040 forecast shows an avg of $10.22 with a max of $20.15, indicating potential to reach around $10 by 2040, though it is not guaranteed.
Current price is $4.30 and the market cap is $132.34M.
The 2050 forecast shows min $9.36, avg $20.80, max $46.08 with ROI 383.7 and a BULLISH sentiment.
AVITA Medical, Inc. Community Discussion
0Share your AVITA Medical, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.